We have located links that may give you full text access.
Unenhanced CT and MRI Parameters That Can Be Used to Reliably Predict Fat-Invisible Angiomyolipoma.
AJR. American Journal of Roentgenology 2016 Februrary
OBJECTIVE: The objective of our study was to determine unenhanced CT and MRI parameters that can be used to reliably predict fat-invisible angiomyolipoma (AML).
MATERIALS AND METHODS: A total of 152 patients with 155 histologically proven renal cell carcinomas (RCCs) and 16 patients with 18 histologically proven AMLs were included. No AML measured less than -20 HU on CT images. The tumor-to-cortex ratio was measured on unenhanced CT, T2-weighted MRI, and T1-weighted MRI to compare fat-invisible AML and RCC. On chemical-shift MRI, the signal intensity (SI) index and tumor-to-spleen ratio were calculated to compare these lesions. The unpaired t test and ROC with AUC were used for statistical analysis. The reference standard was pathologic examination.
RESULTS: The mean tumor-to-cortex ratios on unenhanced CT of AML and RCC were 1.37 ± 0.66 (SD) and 0.83 ± 0.47, respectively (p < 0.001). However, the tumor-to-cortex ratio on unenhanced CT of AML was not different from that of chromophobe RCC (p = 0.093). The mean tumor-to-cortex ratios on T2-weighted MRI of AML and RCC were 0.75 ± 0.15 and 1.21 ± 0.41, respectively (p < 0.001). However, the tumor-to-cortex ratio on T2-weighted MRI of AML was not different from that of papillary RCC (p = 0.161). The tumor-to-spleen ratio on chemical-shift MRI, tumor-to-cortex ratio on T1-weighted MRI, and SI index on chemical-shift MRI of AML were not different from those of RCC (p = 0.104-0.670). The AUCs of the tumor-to-cortex ratio on T2-weighted MRI and the tumor-to-cortex ratio on unenhanced CT were 0.862 and 0.835, respectively.
CONCLUSION: The tumor-to-cortex ratio on T2-weighted MRI and the tumor-to-cortex ratio on unenhanced CT are good parameters to differentiate fat-invisible AML from clear cell RCC. Nevertheless, percutaneous biopsy is necessary because these parameters are not reliable in differentiating fat-invisible AML from non-clear cell RCC.
MATERIALS AND METHODS: A total of 152 patients with 155 histologically proven renal cell carcinomas (RCCs) and 16 patients with 18 histologically proven AMLs were included. No AML measured less than -20 HU on CT images. The tumor-to-cortex ratio was measured on unenhanced CT, T2-weighted MRI, and T1-weighted MRI to compare fat-invisible AML and RCC. On chemical-shift MRI, the signal intensity (SI) index and tumor-to-spleen ratio were calculated to compare these lesions. The unpaired t test and ROC with AUC were used for statistical analysis. The reference standard was pathologic examination.
RESULTS: The mean tumor-to-cortex ratios on unenhanced CT of AML and RCC were 1.37 ± 0.66 (SD) and 0.83 ± 0.47, respectively (p < 0.001). However, the tumor-to-cortex ratio on unenhanced CT of AML was not different from that of chromophobe RCC (p = 0.093). The mean tumor-to-cortex ratios on T2-weighted MRI of AML and RCC were 0.75 ± 0.15 and 1.21 ± 0.41, respectively (p < 0.001). However, the tumor-to-cortex ratio on T2-weighted MRI of AML was not different from that of papillary RCC (p = 0.161). The tumor-to-spleen ratio on chemical-shift MRI, tumor-to-cortex ratio on T1-weighted MRI, and SI index on chemical-shift MRI of AML were not different from those of RCC (p = 0.104-0.670). The AUCs of the tumor-to-cortex ratio on T2-weighted MRI and the tumor-to-cortex ratio on unenhanced CT were 0.862 and 0.835, respectively.
CONCLUSION: The tumor-to-cortex ratio on T2-weighted MRI and the tumor-to-cortex ratio on unenhanced CT are good parameters to differentiate fat-invisible AML from clear cell RCC. Nevertheless, percutaneous biopsy is necessary because these parameters are not reliable in differentiating fat-invisible AML from non-clear cell RCC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app